News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Why 2017 Will be a Data-Rich and Not Revenue-Focused Year for bluebird bio (BLUE) 2/24/2017
Tocagen Receives Breakthrough Therapy Designation From FDA For Toca 511 & Toca FC In Recurrent High Grade Glioma 2/23/2017
Reata Pharmaceuticals, Inc. Announces Initiation Of Phase II/III Study Of Bardoxolone Methyl In The Treatment Of Chronic Kidney Disease Due To Alport Syndrome 2/23/2017
Madrigal Announces The Initiation Of A Phase II Study Of MGL-3196 In Patients With Heterozygous Familial Hypercholesterolemia (HeFH) 2/23/2017
Resverlogix (RVX.TO) Reports Positive FDA Type B Meeting On Design Issues Relating To A Proposed Phase IIa Kidney Dialysis Trial 2/23/2017
Tocagen Achieves Key Development Milestone For Lead Product: Phase II Randomized Trial In Patients With Recurrent Brain Cancer Fully Enrolled 2/23/2017
OncoSec Medical Announces Positive Phase II Data Demonstrating Company's ImmunoPulse IL-12 In Combination With Pembrolizumab Increased Response Rates In Anti-PD-1 Non-Responder Melanoma Patients 2/23/2017
Minoryx Therapeutics Receives Orphan Drug Designation From The FDA For Its Lead Candidate MIN-102 2/22/2017
Soligenix (SNGX) Receives European Patent For Formulation Of Synthetic Hypericin To Treat Psoriasis 2/22/2017
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Continues To Demonstrate Early Evidence Of Efficacy Following Completion Of Idiopathic Pulmonary Fibrosis Phase II Clinical Trial 2/22/2017
Kalytera Therapeutics Announces Encouraging Results Of A Phase IIa Clinical Study For The Treatment Of Acute Graft Versus Host Disease 2/22/2017
Touchstone Innovations Plc Portfolio Company Cell Medica Granted FDA Fast Track Designation For Lead Oncology Product 2/21/2017
Immuron Completes Phase II NASH Clinical Trial Recruitment 2/21/2017
Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA Fast Track Designation 2/21/2017
OncoGenex (OGXI) Announces Phase II Apatorsen Data For Two Clinical Trials Presented At The OncoGenex (OGXI) 2017 Genitourinary Cancers Symposium 2/21/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis 2/21/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis 2/21/2017
OncoGenex (OGXI) Release: Data Support Continued Exploration Of Hsp27 Inhibition In Bladder And Prostate Cancers 2/21/2017
SoCal's Cidara (CDTX) Stock Sinks as Lead Antifungal Med Flunks Trial 2/21/2017
Lysogene Receives Orphan Drug Designation From EMA For LYS-GM101 For Treatment Of GM1 Gangliosidosis 2/21/2017
3 Biotechs With the Biggest and Most Promising Pipelines 2/20/2017
After Merck & Co. (MRK) & Eli Lilly (LLY) Alzheimer’s Failures, A Look at 7 Companies Still on the Hunt 2/20/2017
Xencor Release: Igg4-Related Disease Biomarker Development Update Presented From An Ongoing, Open-Label, Phase II Study Of Xmab5871 In Igg4-RD At The 3rd International Symposium On Igg4-Related Diseases & Fibrosis 2/20/2017
Hutchison China MediTech (Chi-Med) Initiates A Phase II Study Of Savolitinib In Pulmonary Sarcomatoid Carcinoma 2/20/2017
Phase II Study Supports Potential For Genentech (RHHBY)’s Tecentriq (Atezolizumab) Plus Avastin (Bevacizumab) For People With Locally Advanced Or Metastatic Renal Cell Carcinoma 2/20/2017
Could Marijuana Be the Next Miracle Drug For Treating Cancer? 2/20/2017
ASLAN Receives Orphan Drug Designation In Korea For Varlitinib (ASLAN001) In Biliary Tract Cancer 2/20/2017
Bionomics Limited (BNO.AX) Release: New BNC105 Clinical Trial In Combination With Keytruda 2/20/2017
ArmaGen Reports Preliminary Evidence Of Cognitive Improvement In Children With Hurler Syndrome (MPS I) Treated With AGT-181 2/17/2017
Ascendis Announces Publication Of Comprehensive Results From Randomized, Active-Controlled Phase 2 Trial Of Once-Weekly Transcon Growth Hormone In Pediatric Patients 2/17/2017
Viriom Reports Positive Findings In Phase IIb Study Of Elpida As Compared To Efavirenz In Combination With TDF/FTC At CROI 2017 2/17/2017
Kalytera Therapeutics To Announce Phase IIa Clinical Study Results Investigating CBD For The Treatment Of Acute Graft Versus Host Disease 2/17/2017
Adamas Pharma (ADMS) To Present New ADS-5102 Data From Phase II Trial In Walking Impairment Associated With Multiple Sclerosis At ACTRIMS Forum 2017 2/17/2017
Heat Biologics Presents Immune Data On Its HS-410 Phase II Bladder Cancer Trial At The Genitourinary Cancers Symposium 2/17/2017
Capricor Therapeutics, Inc. Terminates Natriuretic Peptide Program Deal With The Mayo Clinic 2/17/2017
Noble Capital Markets Initiates Research Coverage On ESSA Pharma 2/17/2017
Another Drug Bites the Dust: Merck & Co. (MRK) Stops Late-Stage Alzheimer’s Study 2/16/2017
Data Presented At CROI Show CytoDyn (CYDY)’s Pro 140 As A Single Agent Provided Maximal Virologic Suppression In HIV Patients For Nearly Two Years 2/16/2017
ArmaGen CEO: Phase II Data Shows Cognitive Improvement in Juvenile Hurler Syndrome Patients 2/16/2017
AEterna Zentaris (AEZS) Announces Zoptrex Presentation In Prostate Cancer At 2017 Genitourinary Cancers Symposium 2/15/2017
Berg Initiates Phase I/II Monotherapy Trial Of BPM 31510-IV In Patients With Glioblastoma Multiforme (GBM) 2/15/2017
TapImmune (TPIV) Advances TPIV 200 Phase II Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review 2/15/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Hutchison China MediTech (Chi-Med) And AstraZeneca PLC (AZN) Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium 2/14/2017
Hutchison China MediTech (Chi-Med): Savolitinib PRCC Results Presentation At ASCO GU 2/14/2017
Aviragen (AVIR) Tanks Some More After Reporting a Second Trial Failure This Month 2/14/2017
Two-Year Update From CytoDyn (CYDY)’s PRO 140 Monotherapy Study In HIV To Be Featured In Two Events At CROI 2017 2/14/2017
Gilead (GILD) Presents New Phase II Data On Bictegravir, An Investigational Integrase Strand Transfer Inhibitor For The Treatment Of HIV 2/14/2017
Sanofi (SNY) Initiates Phase II Clinical Trial To Evaluate Therapy For Genetic Form Of Parkinson’s Disease 2/14/2017
Axovant (AXON) Clears an Early Hurdle in Mid-Stage Dementia Trial, But Questions Remain 2/13/2017
SAGE Therapeutics (SAGE) Advances SAGE-217 Into Placebo-Controlled Phase 2 Clinical Trial In Major Depressive Disorder 2/13/2017
DelMar Pharma Announces Dosing Of The First Patient In Phase Two Clinical Trial Of VAL-083 For MGMT-Unmethylated Recurrent Glioblastoma Multiforme (GBM) 2/13/2017
Trek Therapeutics Announces Oral Presentation Of Faldaprevir, TD-6450 And Ribavirin Ph2a Trial Results At The Asian Pacific Association For The Study Of The Liver On February 18, 2017 In Shanghai 2/13/2017
Biotron Limited (BIT:AU) Release: Commencement Of BIT225 Phase ll HIV-1 Clinical Trial 2/13/2017
MMJ PhytoTech Phase ll Clinical Trial For Treatment of Epilepsy Underway 2/13/2017
TRACON Pharma (TCON) Announces Top-Line Results From NCI-Sponsored Phase 2 Trial Of TRC105 In Recurrent Glioblastoma 2/10/2017
Neuraltus Pharmaceuticals, Inc. Provides Enrollment Update On Confirmatory Phase II Study Of NP001 In ALS 2/9/2017
Jazz Pharma (JAZZ) Announces First Patient Enrolled In Phase II Clinical Study Evaluating JZP-110 For Excessive Sleepiness In Parkinson's Disease 2/9/2017
ASLAN Reports Positive Top-Line Results For Phase II Clinical Trial Of Varlitinib In Metastatic Breast Cancer 2/9/2017
Iconic Therapeutics, Inc. To Present Phase IIa EMERGE Trial Results At Miami Meeting 2/9/2017
VM BioPharma Announces Publication Of Phase I/II Clinical Data Of Novel Gene Therapy VM202 In Amyotrophic Lateral Sclerosis (ALS) 2/9/2017
Boehringer Ingelheim Release: Afatinib To Be Evaluated In Combination With PD-1 Inhibitor Pembrolizumab In New Trial For Patients With Squamous Cell Carcinoma Of The Lung 2/9/2017
Boehringer Ingelheim Release: Afatinib To Be Evaluated In Combination With PD-1 Inhibitor Pembrolizumab In New Trial For Patients With Squamous Cell Carcinoma Of The Lung 2/9/2017
New FDA Report Cites 22 Drugs That Passed Phase II But Crashed and Burned in Phase III 2/8/2017
MeiraGTx Provides Clinical Trial Updates For Achromatopsia And Leber's Congenital Amaurosis Ocular Gene Therapy Programs 2/8/2017
CRT Pioneer Fund And Cardiff University Announce The Initiation Of The Phase II MONOCLE Study Of Tefinostat For The Treatment Of Chronic Myelomonocytic Leukaemia With Funding To Progress Further Development 2/8/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Aldeyra (ALDX) Announces First Patient Enrolled In Allergic Conjunctivitis Phase IIb Clinical Trial 2/7/2017
Immuron Announces First Patient Enrolled In Pediatric Fatty-Liver Phase II Trial 2/7/2017
GW Pharma (GWPH) Achieves Positive Results In Phase II Proof Of Concept Study In Glioma 2/7/2017
Another Letdown for Bristol-Myers Squibb (BMY) as Partner Innate Pharma (IPH.PA )'s Leukemia Candidate Flunks Phase II Test 2/6/2017
These 5 Biotechs Are Battling Over the $10 Billion Hemophilia Market 2/6/2017
Zealand Pharma  (ZEAL.CO) Release: Patient Recruitment Completed For Phase II Trial With Glepaglutide For Treatment Of Short Bowel Syndrome 2/6/2017
5 Daring Biopharmas Mixing Drugs With Marijuana 2/6/2017
Addex Therapeutics (ADXN.SW)' Clinical Programs And Discovery Platform Highlighted In Review Of Allosteric Modulators For The Treatment Of Neurodegenerative Diseases 2/6/2017
Sirnaomics Initiates A Clinical Phase IIa Study Of Its Leading Sirna Therapeutic Candidate, STP705, For Treatment Of Hypertrophic Scar 2/6/2017
3rd Stemline (STML) Patient Died in Clinical Trial One Day Before $45 Million Public Offering 2/3/2017
Pharmazz Initiates Human Phase II Studies Of PMZ-2010 For The Treatment Of Hemorrhagic Shock And Presents Data At The Society Of Critical Care Medicine Annual Meeting 2/3/2017
Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma 2/3/2017
DBV Tech Announces Completion Of Enrollment Of Phase IIA Study Of Viaskin Milk For The Treatment Of Pediatric Eosinophilic Esophagitis 2/3/2017
Why This Big Biotech Could be Biogen (BIIB)'s Downfall 2/3/2017
Pfizer (PFE) Quietly Kills 3 Pipeline Programs 2/2/2017
BioMarin (BMRN) Receives Access To Priority Medicines (PRIME) Regulatory Support From EMA For BMN 270 Gene Therapy In Hemophilia A 2/2/2017
Galapagos (GLPG.BR) Doses First Patient With Novel CF Corrector GLPG2222 2/2/2017
Aviragen (AVIR) Craters as RSV Antiviral Flops in Phase IIa Study 2/2/2017
TapImmune (TPIV) Completes Scale-Up And GMP Manufacturing Of TPIV 200 Vaccine To Supply Additional Phase 2 Clinical Trials 2/2/2017
Audentes (BOLD) Announces FDA Clearance Of Investigational New Drug Application For AT342 To Treat Crigler-Najjar Syndrome 2/1/2017
Medivir (MVRBF) Release: MIV-711 Osteoarthritis Trial: Successful Fourth Independent Review Of Safety Data Enables Trial Continuation Without Any Modifications 2/1/2017
6 Biopharma Companies Face Catalysts in February 1/31/2017
Seres Therapeutics (MCRB) Takes a Magnifying Glass to Failed Phase II, Wants a Do-Over 1/31/2017
Repros Therapeutics (RPRX) Release: FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex In The Treatment Of Uterine Fibroids 1/31/2017
TiGenix Enrolls First Patient iIn Phase Ib/IIa Clinical Trial Of Cx611 In Severe Sepsis 1/31/2017
Angion Biomedica Corp.'s Phase 2 “GUARD” Clinical Trial Of BB3 In Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study In Renal Transplant Recipients With Delayed Graft Function (DGF) 1/31/2017
Aevi Genomic Medicine Announces Enrollment Of First Patient In Phase 1/2 Clinical Trial Of AEVI-001 In 22q Deletion Syndrome 1/31/2017
Bay Area's Ocera Therapeutics (OCRX) Plunges as Lead Drug Flunks Mid-Stage Hepatic Encephalopathy Study 1/30/2017
uniQure (QURE) Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B 1/30/2017
Advaxis (ADXS) Release: GOG-0265 Study In Metastatic Cervical Cancer Selected For Late-Breaking Data Presentation At The Society Of Gynecologic Oncology’s Annual Meeting On Women’s Cancer 1/30/2017
Acucela (AUCL) Initiates Phase 2a Study Of Emixustat Hydrochloride Addressing Patients With Stargardt Disease 1/27/2017
Relmada Therapeutics Release: Announces FDA Acceptance Of IND And Authorization To Commence Phase 2a Clinical Trial For D-Methadone 1/26/2017
Pfizer (PFE) Release: Company Touts Positive Mid-Stage Data for Clostridium difficile Vaccine 1/26/2017
Scientists Highlight the Hopes and Fears of Cellectis (ALCLS)' CAR-T 1/26/2017
Biomay AG Release: Company Reports Positive Results From A Second Phase Ilb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine Bm32 1/26/2017
4SC (VSC.F) Release: Overall Survival Benefit For Resminostat In First-Line Liver Cancer Study Subgroup 1/26/2017
Caladrius Biosciences (CLBS) Release: Biotech Announces Addition Of Three Clinical Sites, Including UCSF, For The Ongoing Phase 2 Study Of CLBS03 In T1D 1/25/2017
AbbVie (ABBV) Release: Pharma Initiates Phase 2 Clinical Trial Programs For ABBV-8E12, An Investigational Anti-Tau Antibody, In Early Alzheimer's Disease And Progressive Supranuclear Palsy 1/25/2017
Novartis AG (NVS) Shows Off 13 Potential Blockbusters in Pipeline 1/25/2017
DelMar Pharma Release: Company And MD Anderson Cancer Center Initiate New Phase Two Clinical Trial Of VAL-083 For MGMT-Unmethylated Recurrent Glioblastoma Multiforme (GBM) 1/25/2017
ProMetic Life Sci (PFSCF.PK) Release: Company's PBI-4050 Receives Promising Innovative Medicine Designation From The UK MHRA For The Treatment Of Alström Syndrome 1/24/2017
TapImmune (TPIV) Release: Pharma Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial 1/24/2017
Genmab A/S (GEN.CO) Release: Company Provides Clinical And Regulatory Update For NCX 470 For IOP Lowering 1/24/2017
Arsanis Release: Biopharma Announces First Patient Dosed In Global Phase 2 Study Of ASN100 For Prevention Of Staphylococcus Aureus Pneumonia 1/24/2017
Flex Pharma (FLKS) Release: Company Focuses On Phase 2 Clinical Programs In Severe Neurological Diseases 1/24/2017
BeyondSpring Pharmaceuticals Release: FDA Accepts Company IND Application For Plinabulin For The Prevention Of Chemotherapy-Induced Neutropenia 1/24/2017
Asterias Biotherapeutics Release: Biotech Announces Additional Motor Function Improvement At 6-Months And 9-Months Following Treatment With AST-OPC1 In Patients With Complete Cervical Spinal Cord Injuries 1/24/2017
Kamada Ltd. (KMDA) Release: Company Announces Positive Scientific Advice Response From The EMA Focused On Alpha-1 Antitrypsin IV For Treatment Of Acute Graft-Versus-Host Disease 1/23/2017
Marinus Pharma (MRNS) Release: Troubled Biotech Finally Gets Some Positive Trial Data 1/23/2017
Sanifit Release: Biopharma Announces Enrollment Of First Patient In CaLIPSO – A Phase Ilb Study For The Treatment Of Cardiovascular Calcification In End-Stage-Renal-Disease Patients On Haemodialsis 1/23/2017
Novavax (NVAX) Initiates Phase II Safety And Immunogenicity Trial Of The RSV F Vaccine In Older Adults 1/20/2017
Concert Pharmaceuticals, Inc. (CNCE) Release: Biopharma Receives FDA Orphan Drug Designation For CTP-656 For The Treatment Of Cystic Fibrosis 1/20/2017
Prima Biomed (PRR.AX) Release: Company Commences Randomised Phase IIb Clinical Trial For IMP321 In Breast Cancer 1/20/2017
Abeona Therapeutics Release: Company Receives Orphan Drug Designation In The European Union For ABO-101 Gene Therapy In Sanfilippo Syndrome Type B 1/19/2017
Otonomy (OTIC) Release: Company Initiates Patient Enrollment In Phase II Clinical Trial Of OTO-104 As Protectant Against Cisplatin-Induced Hearing Loss 1/19/2017
Dermata Therapeutics Release: Company Announces Initiation Of Treatment In A Phase 2 Acne Rosacea Clinical Study 1/19/2017
Synthetic Biologics (SYN) Release: Company Confirms Key Features Of Pivotal Phase 2b/3 Trial Of SYN-010 Pursuant To Consultations With FDA 1/19/2017
ARCA biopharma Release: Company Announces 150th Patient Randomized Into The GENETIC-AF Phase IIB/III Clinical Trial 1/18/2017
ProMetic Life Sci (PFSCF.PK) Releaase: European Commission (EC) Grants Orphan Drug Designation To Company's PBI-4050 Drug For The Treatment Of Alström Syndrome 1/18/2017
aTyr Pharma Release: FDA Grants Fast Track Designation For Company's Resolaris To Treat Limb Girdle Muscular Dystrophy 2B And Removes Partial Clinical Hold For Resolaris 1/18/2017
Tarix Orphan Release: Company Receives Rare Pediatric Disease Designation For TXA127 For Recessive Dystrophic Epidermolysis Bullosa (RDEB) 1/18/2017
Daiichi Sankyo Release: Company Initiates Phase 1/2 Study Of Novel Antibody Drug Conjugate U3-1402 In Patients With HER3-Positive Metastatic Or Unresectable Breast Cancer 1/18/2017
Neurocrine Biosciences (NBIX) Release: SoCal Biotech's Tourette Drug Flunks Phase II Study 1/18/2017
Kura Oncology Doses First Patient In Phase II Study Of Tipifarnib In Chronic Myelomonocytic Leukemia 1/17/2017
Concert Pharmaceuticals, Inc. (CNCE) Release: Company Provides Further Details On CTP-656 Development In U.S. And Europe 1/17/2017
Protagonist (PTGX) Release: Pharma Initiates Phase 2b Study Of Oral Drug Candidate PTG-100 In Ulcerative Colitis 1/17/2017
BioLineRx Release: Pharma Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA For Pancreatic Cancer 1/17/2017
Agenus (AGEN) Release: Company Announces Collaboration With The NCI To Evaluate The Combination Of Pembrolizumab (Keytruda, Merck & Co. (MRK)) With Prophage (Agenus Inc.) Autologous Vaccine 1/17/2017
Psyadon Release: Company Announces Positive Results From Phase IIb Clinical Study Of Ecopipam For The Treatment Of Tourette’s Syndrome In Children 1/17/2017
Corbus (CRBP) Release: Pharma Receives Orphan Designation For JBT-101 For The Treatment Of Systemic Sclerosis In The European Union 1/17/2017
AiCuris Release: Pharma Announces Publication Of Phase 2 Clinical Trial Results Of Investigational Anti-Herpes Simplex Virus Agent Pritelivir In JAMA 1/17/2017
JPM17: Why the Key to Gene Therapy Could be in an Old Bay Area Warehouse 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Biopharma Initiates A Phase II Study Of Sulfatinib In Second-Line Biliary Tract Cancer In China 1/16/2017
Sunovion Release: Biopharma Announces Pivotal Study Results For Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms In Children Compared To Placebo 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Biopharma Initiates A Phase II Combination Study Of Fruquintinib With Iressa (Gefitinib) In First-Line Non-Small Cell Lung Cancer 1/16/2017
Tocagen Release: Company Expands Toca 5, Phase II/III Clinical Trial For Recurrent Brain Cancer, To South Korea 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Sulfatinib Phase II Study In 2nd Line BTC In China 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Fruquintinib Combination Study In 1st-Line NSCLC 1/16/2017
Sunovion Release: Massachusetts Biotech Touts Binge Eating and ADHD Mid-Stage Trials Data 1/13/2017
JPM17: CureVac Release: Biotech's mRNA Program Fails Phase II Test, Putting Spotlight on Other Biotechs Like Moderna 1/12/2017
Delcath Systems (DCTH) Release: Company Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort 1/12/2017
MorphoSys AG Release: Company Partner To Start Phase 2 Trial With Bimagrumab In Obese Patients With Type 2 Diabetes 1/12/2017
Shionogi Release: Pharma Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial 1/12/2017
BioPharmX Release: Pharma Data Suggest Anti-Inflammatory Activity Of BPX-01 Topical Minocycline Gel 1/12/2017
JPM17: How Celgene (CELG) Wowed Yet Again 1/11/2017
Sangamo (SGMO) Release: Pharma Receives Orphan Drug Designation From The FDA For SB-318 Genome Editing Treatment For MPS I 1/11/2017
Vtesse Announces Dosing Of First Patient In Australia In Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 1/11/2017
CytoDyn (CYDY) Release: Biotech Files For Breakthrough Therapy Designation With The FDA For PRO 140 In HIV Therapy 1/11/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Sobi Release: First Patient Randomized In A Phase II Study Evaluating The Safety And Efficacy Of Anakinra In The Treatment Of Acute Gout 1/11/2017
Visterra, Inc. Release: Pharma Doses First Patient In Phase 2a Trial For VIS410, Its Monoclonal Antibody In Development For The Treatment Of Hospitalized Patients With Influenza A 1/11/2017
Finding a Complementary Secondary Endpoint in Lupus Clinical Trials 1/10/2017
G1 Therapeutics Release: Biotech Initiates Three Drug Development Programs In Breast Cancer 1/10/2017
TapImmune (TPIV) Release: Pharma Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients 1/10/2017
Sangamo (SGMO) Release: Company Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering 1/10/2017
Debiopharm Release: Biopharma Announces Positive Phase 2 Clinical Trial With Debio 1450 In ABSSSI Patients 1/10/2017
The Jackson Laboratory Release: Mark Adams Joins Company As Director, Microbial Genomic Services 1/10/2017
ThromboGenics NV (TBGNF) Release: Pharma Enrolls First Patients In Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) For Diabetic Macular Edema (DME) 1/10/2017
Galmed Pharmaceuticals Completes Patient Recruitment For ARREST Phase IIb NASH Study 1/9/2017
Can-Fite BioPharma (CFBI) Receives IRB Approval To Commence Patient Enrollment In Phase II NAFLD/NASH Trial In Q1 2017 1/9/2017
Menlo Therapeutics Starts Enrollment In Two Phase 2 Studies For Pruritus Associated With Atopic Dermatitis And Pruritus Following Burn Injury 1/9/2017
Probiodrug AG Announces Completion Of Recruitment For The SAPHIR Phase 2a Study Of Glutaminyl Cyclase Inhibitor PQ912 In Early Alzheimer's Disease Patients 1/9/2017
PTC Therapeutics (PTCT) Provides Corporate Update And Outlines 2017 Strategic Priorities To Maximize The Global Value Of Translarna And Advance Its Innovative Pipeline 1/9/2017
The Medicines Company (MDCO) Announces Positive Top-Line Results From Day 180 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of Inclisiran (Formerly, PCSK9si) 1/9/2017
Aridis Pharma Reports Positive Clinical Data From Phase 1/2a Study Of Human Monoclonal Antibody AR-301 For Treating Pneumonia 1/6/2017
Genprex Announces Positive Interim Data From Phase II Clinical Trial Of Oncoprex For Late Stage Non-Small Cell Lung Cancer 1/6/2017
Neurocrine Biosciences (NBIX) Provides Update On FDA Advisory Committee For INGREZZA (Valbenazine) For The Treatment Of Tardive Dyskinesia 1/6/2017
PTC Therapeutics (PTCT) Release: RG7916 Granted Orphan Drug Designation In The U.S. For The Treatment Of Spinal Muscular Atrophy 1/6/2017
Mirati Therapeutics  (MRTX) Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs 1/6/2017
DS Biopharma Announces That Recruitment Has Begun In Two Separate Phase 2b Atopic Dermatitis Studies With Lead Compound DS107 As Well As The Successful Completion Of A Phase 1 Trial For Follow On Compound DS109 1/6/2017
TLC Biopharmaceuticals, Inc. Reports Results Of Phase 1/2 Clinical Trial Of TLC599 For Sustained Pain Relief In The Treatment Of Osteoarthritis Of The Knee 1/6/2017
Puma Biotech (PBYI) Expands Cohort In Phase II SUMMIT Trial Of PB272 In HER2 Mutation-Positive Cancer Patients 1/6/2017
Viamet Reports Positive Results From RENOVATE Phase 2b Trial Of Oral VT-1161 In Onychomycosis 1/6/2017
Viamet Reports Positive Results From REVIVE Phase 2b Trial Of Oral VT-1161 In Recurrent Vulvovaginal Candidiasis 1/6/2017
Janssen Biotech (JNJ) Enters Immunotherapy Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Daratumumab (DARZALEX) In Combination With Nivolumab (OPDIVO) 1/5/2017
Halozyme (HALO) Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints 1/5/2017
Synthetic Biologics (SYN)' SYN-004 (Ribaxamase) Achieves Primary Endpoint In Phase 2b Trial For C. Difficile Infection (CDI) 1/5/2017
Gemphire Provides Clinical Update 1/5/2017
Cascadian Therapeutics (ONTY) Announces 2017 Outlook And Recent Drug Portfolio Progress 1/5/2017
Soligenix (SNGX) Receives Positive Scientific Advice From The EMA For SGX942 In The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 1/5/2017
Rigel (RIGL) Provides Business Updates And Preliminary Data In IgA Nephropathy 1/5/2017
Xigen S.A.’s Brimapitide, An Innovative JNK Inhibitor, Delivers Positive Phase II Results In Inflammatory Eye Disease 1/5/2017
Heron (HRTX) Announces Positive Topline Results From Phase 2 Clinical Trial Of HTX-011 In Abdominoplasty 1/5/2017
Heron (HRTX) Establishes Synergy Of Bupivacaine And Meloxicam With HTX-011 For Prevention Of Post-Operative Pain In Phase 2 Clinical Studies 1/5/2017
Genocea (GNCA) Announces Positive 6-Month Results From GEN-003 Phase 2b Clinical Trial 1/5/2017
Ritter Pharmaceuticals, Inc. Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published In PNAS 1/4/2017
Lycera Announces Initiation Of Phase 1/2a Study ARGON Of Immuno-Oncology Candidate LYC-55716 In Patients With Advanced Solid Tumors 1/4/2017
Ionis Pharma (IONS) Reports Positive Data From Phase 2 Study Of IONIS-GCGR Rx In Patients With Type 2 Diabetes 1/4/2017
US FDA Grants Orphan Drug Designation To YiSheng BioPharma's PIKA Rabies Vaccine 1/4/2017
Senhwa Biosciences CX-4945 Granted Orphan Drug Designation By The US FDA In Cholangiocarcinoma 1/4/2017
BioPharmX Completes Enrollment Of BPX-01 Phase 2b OPAL Clinical Trial For Acne Vulgaris 1/4/2017
NeuroRx Announces FDA IND Clearance For NRX-101 Phase 2b/3 Study And Publication Of Promising Biomarker Data 1/4/2017
Ogeda Announces Positive Data From Phase IIa Trial Of Fezolinetant (ESN364) In The Treatment Of Menopausal Hot Flashes 1/4/2017



//-->